MAPT and Alzheimer disease: Based on the high-risk or low-risk dichotomy for a further progression to clinical AD, we propose to consider the terms of “preclinical AD” when the risk is particularly high (e.g., both Aß and Tau markers beyond pathologic thresholds) and that of AR-AD when the evolution to a clinical AD is less likely or still needs to be determined (only one pathophysiological marker considered abnormal).